Solana Company Stock Price, News & Analysis

Helius Medical Technologies (Nasdaq: HSDT) announced the addition of Oregon Health & Science University to its Therapeutic Experience Program, aiming to evaluate the effects of PoNS therapy for gait improvement in patients with multiple sclerosis (MS). The study is a multi-center, open-label trial to assess adherence to the PoNS device combined with physical therapy. Enrollment is expected to start in Q4 2022, targeting 50-60 MS patients across 10-12 Centers of Excellence in the U.S. Key endpoints include maintenance of gait improvement and overall functional outcomes.

Helius Medical Technologies will showcase its innovative Portable Neuromodulation Stimulator (PoNS®) at the ACRM Conference in Chicago from November 8-11. Visitors to booth 512 can explore how PoNS aids those with multiple sclerosis (MS) in improving gait deficiencies. The device uses electrical impulses through the tongue to stimulate neural pathways, enhancing mobility. Physical therapists can register for free online training to maximize the effectiveness of PoNS therapy. Helius is committed to supporting MS patients as 70% report mobility challenges.

Helius Medical Technologies (NASDAQ: HSDT) will release its Q3 2022 financial results on November 14, 2022, before the market opens. Following this, CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen will host a conference call at 8:30 a.m. ET to discuss the results and provide insights into the commercialization of PoNS®. The call can be accessed via registration, and a webcast will be archived for later viewing on the company’s investor relations website.

Helius Medical Technologies emphasizes its gratitude towards physical therapists skilled in using the Portable Neuromodulation Stimulator (PoNS^®) during National Physical Therapy Month. The company aims to expand online training for therapists to enhance treatment for individuals with multiple sclerosis (MS). Clinical trials show that PoNS therapy significantly improves gait, with 58.3% of MS patients achieving notable gait enhancement. Helius is fostering a growing community of trained professionals to further support MS patients' mobility and quality of life.

Helius Medical Technologies (Nasdaq:HSDT) announced that its executives, Dane Andreeff and Jeff Mathiesen, will present at the ROTH Capital Partners Inaugural Healthcare Opportunities Conference on October 6, 2022, at 8:45 AM ET in New York City. Attendees can arrange 1-on-1 meetings with management through Roth Capital. Helius focuses on neurological wellness and offers the Portable Neuromodulation Stimulator (PoNS®), a device that aids in treating gait deficits associated with multiple sclerosis and traumatic brain injuries. For more information, visit their website.

Helius Medical Technologies (HSDT) announced the approval of an equity award under its 2021 Inducement Plan, as a material inducement for a new employee effective September 13, 2022. The award comprises an option to purchase 10,000 shares at an exercise price of $0.54 per share, matching the closing price on the grant date. The option vests over four years, with 25% vesting annually. Helius is focused on neurological wellness and has developed the Portable Neuromodulation Stimulator (PoNS), aimed at treating gait deficits from conditions like multiple sclerosis.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) announced that its executives will present at two healthcare conferences this September. The first is the H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022), available on demand. The second is the Ladenburg Thalmann Healthcare Conference in New York City on September 29, 2022, at 10:00 AM ET. Helius focuses on neurological wellness and offers the Portable Neuromodulation Stimulator (PoNS), a non-surgical device aimed at improving balance and gait for patients with multiple sclerosis and traumatic brain injury.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) reported Q2 2022 financial results with revenues increasing by 68% to $119K, primarily from PoNS Therapy sales for MS patients. The company initiated U.S. commercial sales and launched a Patient Therapy Access Program to improve accessibility. Operating expenses decreased to $3.5M, leading to a reduced net loss of $3.8M compared to $6.0M in Q2 2021. Cash reserves total $19.7M post-recent financing, expected to fund operations through 2023. The company anticipates modest revenue growth for Q3, driven by continued sales coverage and patient pairing efforts.

Helius Medical Technologies (NASDAQ: HSDT) will release its Q2 2022 financial results on August 15, 2022, after market close. CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen will host a conference call at 4:30 p.m. ET to discuss results and provide updates on the U.S. commercialization of its product, the Portable Neuromodulation Stimulator (PoNS). This innovative device aims to assist individuals with gait deficits due to multiple sclerosis. The conference call requires prior registration for dial-in details.